Evaluation of the Pharmaceutical Industry Investment Program

Productivity Commission

Abstract: With the expiry of the Pharmaceutical Industry Investment Program (PIIP) in 2004, the Commission was asked to conduct an evaluation of the program’s rationale, effectiveness and efficiency. The study commenced in August 2002. The Commission found that this assistance scheme had significant deficiencies and should not be renewed in its current form when it expires.

Keywords: Clause (f); Drugs; Generic drugs; PBAC; PBPA; Pharmaceutical Benefits Advisory Committee; Pharmaceutical Benefits Pricing Authority’s; Pharmaceutical Benefits Scheme; Pharmaceutical Industry; Pharmaceutical Industry Investment Program; PIIP; R&D; Research and Deveoppment; Taxation (search for similar items in EconPapers)
JEL-codes: A (search for similar items in EconPapers)
New Economics Papers: this item is included in nep-com and nep-hea
Date: Written 2003-05-01
Note: Type of Document - PDF; prepared on IBM PC; to print on HP;
View list of references View citations in EconPapers

Downloads: (external link)
http://129.3.20.41/eps/mic/papers/0305/0305001.pdf (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Access Statistics for this paper

More papers in Microeconomics from EconWPA
Series data maintained by EconWPA ().